The circular RNA, CDR1as/ciRS‐7, functions as a vital regulator in various cancers; however, the predictive value of CDR1as remains controversial. Therefore, a comprehensive analysis for clarifying the precise diagnostic and prognostic value of CDR1as in solid tumours is needed. A literature review of several databases was conducted for identifying potential studies. Pooled odds ratios (ORs) and hazard ratios (HRs) were used for evaluating the diagnostic accuracy variables and survival. Overall, 15 studies (1787 patients) and 11 studies (1578 patients) were included for diagnostic and prognostic outcome syntheses, respectively. Up‐regulated CDR1as expression was found to be correlated with worse clinicopathological characteristics, including the T status, N status, histological grade, TNM stage and distant metastasis. The synthesized sensitivity was 0.72 (95% confidence interval [CI], 0.65‐0.79), and the specificity was 0.80 (95% CI, 0.74‐0.86). The positive likelihood ratio (LR), negative LR and diagnostic odds ratio (DOR) were 3.70, 0.34 and 10.80, respectively. The area under the receiver operator characteristic curve was 0.84 (95% CI, 0.80‐0.87). In the pooled prognostic analysis, patients with high CDR1as expression had worse overall survival (HR = 2.40, P < 0.001) and disease‐free survival (HR = 1.74, P < 0.001). These results suggest that CDR1as is a reliable diagnostic and prognostic biomarker with high accuracy and efficiency, which may potentially facilitate clinical decisions on solid tumours in the future.

中文翻译：

---

环状RNA CDR1as / ciRS-7对实体瘤的诊断和预后价值：系统评价和荟萃分析。

环状RNA CDR1as / ciRS-7在多种癌症中起着至关重要的调节作用。然而，CDR1as的预测价值仍存在争议。因此，需要进行全面的分析以阐明CDR1as在实体瘤中的精确诊断和预后价值。为了确定潜在的研究，对几个数据库进行了文献综述。合并的优势比（OR）和危险比（HRs）用于评估诊断准确性变量和生存期。总体而言，分别包括15项研究（1787例患者）和11项研究（1578例患者）用于诊断和预后结果综合。发现上调的CDR1as表达与较差的临床病理特征相关，包括T状态，N状态，组织学分级，TNM分期和远处转移。合成灵敏度为0.72（95％置信区间[CI]，0.65-0.79），特异性为0.80（95％CI，0.74-0.86）。阳性似然比（LR），阴性LR和诊断比值比（DOR）分别为3.70、0.34和10.80。接收器操作员特征曲线下的面积为0.84（95％CI，0.80-0.87）。在合并的预后分析中，高CDR1as表达的患者的总生存期较差（HR = 2.40，P  <0.001）和无病生存期（HR = 1.74，P  <0.001）。这些结果表明，CDR1as是一种可靠的诊断和预后生物标记物，具有很高的准确性和效率，这可能在将来可能促进对实体瘤的临床决策。